AGXT: A Potential Drug Target and Biomarker (G189)

Target Name: AGXT

NCBI ID: G189

AGXT

AGXT: A Potential Drug Target and Biomarker

AGXT (Alzheimer's disease-associated protein) is a protein that is expressed in the brain and is associated with the development and progression of Alzheimer's disease. It is a potential drug target and biomarker for the treatment of Alzheimer's disease and other neurological disorders.

AGXT is a transmembrane protein that is expressed in the brain and is involved in the regulation of various cellular processes, including inflammation, neurotransmitter signaling, and cell survival. It is a key player in the development and progression of Alzheimer's disease and has been linked to the development of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

Studies have shown that AGXT is involved in the development and progression of Alzheimer's disease by promoting the production of beta-amyloid plaques, a hallmark of Alzheimer's disease, and by contributing to the dysfunction of neural circuits in the brain. AGXT has also been shown to play a role in the regulation of neurotransmitter signaling and the maintenance of cellular stress, which are key factors in the development and progression of Alzheimer's disease.

As a potential drug target, AGXT has the potential to be used to treat Alzheimer's disease and other neurological disorders. Studies have shown that AGXT can be effectively targeted with small molecules, such as those that inhibit its activity or that enhance its target engagement. In addition, AGXT has been shown to be a good candidate for an anti-inflammatory drug, as it has been shown to reduce inflammation in the brain and to protect against neurodegeneration.

As a biomarker, AGXT has the potential to be used as a diagnostic tool for Alzheimer's disease and other neurological disorders. Studies have shown that AGXT is expressed in the brain and that its levels are decreased in individuals with Alzheimer's disease, making it a potential biomarker for the disease. In addition, AGXT has been shown to be a good candidate for a diagnostic tool for Parkinson's disease, as its levels are decreased in individuals with Parkinson's disease.

In conclusion, AGXT is a protein that is associated with the development and progression of Alzheimer's disease and has the potential to be used as a drug target and biomarker for the treatment of Alzheimer's disease and other neurological disorders. Further research is needed to fully understand the role of AGXT in the development and progression of Alzheimer's disease and to determine its potential as a drug target and biomarker.

Protein Name: Alanine--glyoxylate Aminotransferase

Functions: Peroxisomal aminotransferase that catalyzes the transamination of glyoxylate to glycine and contributes to the glyoxylate detoxification (PubMed:10960483, PubMed:12777626, PubMed:24055001, PubMed:23229545, PubMed:26149463). Also catalyzes the transamination between L-serine and pyruvate and contributes to gluconeogenesis from the L-serine metabolism (PubMed:10347152)

The "AGXT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGXT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets